Skip to main content
SpringerLink
Log in

Reduced-Antigen Combined Diphtheria-Tetanus-Acellular Pertussis Vaccine (Boostrix™)

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ The reduced-antigen combined diphtheria-tetanus-acellular pertussis vaccine (dTpa) is intended for use as a booster dose in individuals aged ≥4 years.

  • ▴ A single dose of dTpa elicited generally similar levels of antibodies against pertussis antigens (pertussis toxoid [PT], filamentous haemagglutinin [FHA] and pertactin [PRN]) as a similar monovalent pertussis booster vaccine (ap) in adolescents or adults, irrespective of their prevaccination serological status or vaccination history.

  • ▴ Levels of antibodies directed against diphtheria toxoid were similar in recipients of dTpa or a licensed reduced-antigen combined diphtheria-tetanus booster vaccine (Td). However, levels of antitetanus antibodies were significantly higher in recipients of Td vaccines compared with those receiving dTpa.

  • ▴ Similar serological response rates were observed for anti-PT, -FHA and -PRN between those receiving dTpa or ap and a similar high percentage of recipients of dTpa and the Td vaccines had seroprotective levels of antibodies against diphtheria and tetanus toxoid.

  • ▴ The most frequently reported local adverse reactions following immunisation with dTpa included pain, redness and swelling; general symptoms included fatigue, headache and fever.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Notes

  1. Use of tradenames is for product identification purposes only and does not imply endorsement.

References

  1. Scott PT, Clark JB, Miser WF. Pertussis: an update on primary prevention and outbreak control. Am Fam Physician 1997 Sep 15; 56(4): 1121–8

    PubMed  CAS  Google Scholar 

  2. Rappuoli R. Acellular pertussis vaccines: a turning point in infant and adolescent vaccination. Infect Agents Dis 1996 Jan; 5(1): 21–8

    PubMed  CAS  Google Scholar 

  3. Pertussis: United States, 1997–2000. MMWR Morb Mortal Wkly Rep 2002 Feb 1; 51(4): 73–6

    Google Scholar 

  4. World Health Organization. Pertussis [online]. Available from URL: http://www.who.int [Accessed 2003 May 22]

  5. He Q, Mertsola J. Epidemiology and prevention of pertussis. Curr Opin Pediatr 1997 Feb; 9(1): 14–8

    Article  PubMed  CAS  Google Scholar 

  6. Orenstein WA. Pertussis in adults: epidemiology, signs, symptoms, and implications for vaccination. Clin Infect Dis 1999 Jun; 28 Suppl. 2: S147–50

    Article  PubMed  Google Scholar 

  7. Campins-Marti M, Cheng HK, Forsyth K, et al. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 2001 Dec 12; 20(5–6): 641–6

    Article  PubMed  CAS  Google Scholar 

  8. Kowalzik F, Avila M, Goh H, et al. Prospective multinational study of pertussis infection in infants and their household contacts: first year results [abstract no. 155]. 21st Annual Meeting of the European Society for Paediatric Infectious Diseases; 2003 Apr 9–11; Taormina

  9. Wirsing von Konig CH, Postels-Multani S, Bogaerts H, et al. Factors influencing the spread of pertussis in households. Eur J Pediatr 1998 May; 157(5): 391–4

    Article  PubMed  CAS  Google Scholar 

  10. Advisory Committee on Immunization Practices. Recommended adult immunization schedule United States, 2002–2003 [online]. Available from URL: http://www.cdc.gov/nip/recs/adultschedule.pdf [Accessed 2003 May 22]

  11. Guerin N, Roure C. Immunisation schedules in the countries of the European Union [online]. Available from URL: http://www.eurosurveillance.org/em/v00n00/v00n00.pdf [Accessed 2003 May 7]

  12. GlaxoSmithKline. Boostrix™: Summary of product characteristics. 2003 Feb

  13. Minh NNT, He Q, Ramalho A, et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics 1999 Dec; 104(6): e70–5

    Article  Google Scholar 

  14. Van der Wielen M, Van Damme P, Joossens E, et al. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine 2000 Apr 14; 18(20): 2075–82

    Article  PubMed  Google Scholar 

  15. Turnbull FM, Heath TC, Jalaludin BB, et al. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine 2000 Nov 8; 19(6): 628–36

    Article  PubMed  CAS  Google Scholar 

  16. Hoel T, Wolter JM, Schuerman LM. The use of a reduced-antigen, diphtheria-tetanus-pertussis vaccine for wound management in adults [abstract no. 028]. 21st Annual Meeting of the European Society for Paediatric Infectious Diseases; 2003 Apr 9–11; Taormina

  17. Avenus Pasteur. Tetavax® adsorbed tetanus toxoid vaccine: package insert [online]. Available from URL: http://www.aventispasteur.com/doc/909150.pdf [Accessed 2003 May 22]

  18. Mortimer Jr EA, Wharton M. Diphtheria toxoid. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia (PA): WB Saunders Company, 1999: 140–17

    Google Scholar 

  19. Wassilak SGF, Orenstein WA, Sutter RW. Tetanus toxoid. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia (PA): WB Saunders Company, 1999: 441–74

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Therese M. Chapman & Karen L. Goa

Authors
  1. Therese M. Chapman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen L. Goa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Therese M. Chapman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chapman, T.M., Goa, K.L. Reduced-Antigen Combined Diphtheria-Tetanus-Acellular Pertussis Vaccine (Boostrix™). Drugs 63, 1407–1413 (2003). https://doi.org/10.2165/00003495-200363130-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200363130-00005

Keywords

Search

Navigation